Skip to main content
Lineage Cell Therapeutics Inc. logo

Lineage Cell Therapeutics Inc. — Investor Relations & Filings

Ticker · LCTX ISIN · US53566P1093 LEI · 5299002BI4W22SDF8R25 TA Manufacturing
Open in API
Filings indexed 2,777 across all filing types
Latest filing 2024-12-09 Proxy Solicitation & In…
Country US United States of America
Listing TA LCTX

About Lineage Cell Therapeutics Inc.

https://lineagecell.com/

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel allogeneic cell therapies for unmet medical needs. The company's proprietary platform uses directed differentiation of pluripotent stem cells to manufacture specialized human cells. These "off-the-shelf" cell transplants are designed to replace or support dysfunctional cells in patients with serious conditions, aiming to restore or enhance physiological function. The therapeutic pipeline is focused on degenerative diseases of the eye, such as dry age-related macular degeneration, and neurological conditions, including spinal cord injury. The company leverages its integrated capabilities in cell line development, manufacturing, and delivery to advance its programs.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2024-12-09 English
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Proxy Statement filed on Schedule 14A with the SEC, specifically for a special meeting of shareholders. It includes detailed information about the meeting agenda, voting procedures, and proposals to be voted on, such as approval of issuance of shares and warrants. The document is not an announcement of a report, nor is it a financial report or earnings release. It is a solicitation of proxies for shareholder voting, which fits the definition of Proxy Solicitation & Information Statement (PSI). The document length is substantial (15,000 characters), indicating it is the full proxy statement, not just a notice or announcement. Therefore, the correct classification is PSI with high confidence.
2024-11-29 English
4
Director's Dealing
2024-11-26 English
4
Director's Dealing
2024-11-26 English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP- Mulroy Michael H
Director's Dealing Classification · 100% confidence The document explicitly states 'FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION' and 'STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP'. Form 4 is the standard SEC filing used by corporate insiders (directors, officers, or 10% owners) to report changes in their beneficial ownership of the company's securities. This directly corresponds to the definition of Director's Dealing (insider trades).
2024-11-26 English
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP- Mulroy Michael H
Director's Dealing Classification · 98% confidence The document explicitly mentions 'CHANGES IN BENEFICIAL OWNERSHIP - Mulroy Michael H.' and references 'FORM_4' (which is typically an SEC Form 4 for insider transactions). It is filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE) under regulations concerning foreign corporations. The content describes a report on personal share transactions by an executive/insider. This directly corresponds to the definition of Director's Dealing (DIRS). Although it mentions an attached PDF, the core subject matter is the insider transaction report, not just the announcement of a report's publication.
2024-11-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.